Chronic inducible urticaria

Adults who are 18 years of age or older who have a confirmed chronic inducible urticaria (CINDU) diagnosis for symptomatic dermographism, cold urticaria or cholinergic urticaria for ≥ 4 months, may qualify for this clinical research study. Participants will receive either an investigational oral treatment (active study drug) or placebo. 

Eligible participants must have the condition inadequately controlled with H1-antihistamines at local label-approved doses. Individuals must be willing and able to physically perform the protocol defined provocation test throughout the study based on the subtype of urticaria they have.

Participants will have regular visits with an experienced research team. There is no cost to participate. Eligible participants may be reimbursed for study-related expenses.

Individuals will be asked to visit the study centre about 13 times over a period of about 60 weeks.

For more information about this trial, visit the link below

Study Details | A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines | ClinicalTrials.gov

For more information, please contact:

Dr Nisal Punchihewa
t: 9623 9464
e: [email protected]